TY - JOUR
T1 - The role of the FOLFIRINOX regimen for advanced pancreatic cancer
AU - Conroy, Thierry
AU - Gavoille, Céline
AU - Samalin, Emmanuelle
AU - Ychou, Marc
AU - Ducreux, Michel
PY - 2013/4/1
Y1 - 2013/4/1
N2 - In 2010, the FOLFIRINOX regimen (bolus and infusional 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) emerged as a new option in patients with metastatic pancreatic cancer and a good performance status. However, at that time, some doubts were raised regarding safety issues. Similarly, no data on FOLFIRINOX were published in patients with unresectable/locally advanced or borderline resectable pancreatic cancer. This article presents the available experience with FOLFIRINOX outside clinical trials in metastatic and locally advanced pancreatic cancer patients. The safety of the regimen in patients with biliary stents and in previously treated patients is also described. FOLFIRINOX usage in clinical practice, including modification of the regimen (omission of bolus 5-fluorouracil; FOLFOXIRI regimen), is also presented. These data suggest that a phase III randomized study is warranted to further explore the role of FOLFIRINOX in locally advanced pancreatic cancer.
AB - In 2010, the FOLFIRINOX regimen (bolus and infusional 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) emerged as a new option in patients with metastatic pancreatic cancer and a good performance status. However, at that time, some doubts were raised regarding safety issues. Similarly, no data on FOLFIRINOX were published in patients with unresectable/locally advanced or borderline resectable pancreatic cancer. This article presents the available experience with FOLFIRINOX outside clinical trials in metastatic and locally advanced pancreatic cancer patients. The safety of the regimen in patients with biliary stents and in previously treated patients is also described. FOLFIRINOX usage in clinical practice, including modification of the regimen (omission of bolus 5-fluorouracil; FOLFOXIRI regimen), is also presented. These data suggest that a phase III randomized study is warranted to further explore the role of FOLFIRINOX in locally advanced pancreatic cancer.
KW - Chemotherapy
KW - Irinotecan
KW - Oxaliplatin
KW - Pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=84879605853&partnerID=8YFLogxK
U2 - 10.1007/s11912-012-0290-4
DO - 10.1007/s11912-012-0290-4
M3 - Article
C2 - 23341367
AN - SCOPUS:84879605853
SN - 1523-3790
VL - 15
SP - 182
EP - 189
JO - Current Oncology Reports
JF - Current Oncology Reports
IS - 2
ER -